The Hydration Pharmaceuticals Company Limited
HPC.ASXConsumer Staples
The marketing and sale of liquid, tablet and powder hydration solution products into the North American markets of Canada and the United States.
Market Data
$0.004
+0.3%$1.7M
-100000.0x
$-0.010
0.00%
-0.6%
Latest Earnings
Appendix 4E and Annual Report
27 February 2026
The Hydration Pharmaceuticals Company Limited (ASX: HPC) reported a significant operational restructuring in FY2025, with revenue declining 22.9% to US$2.47M and a net loss of US$2.86M (versus prior-year profit of US$2.67M), following the divestiture of non-US assets and deliberate SKU rationalization prioritizing margin quality over growth. The company reduced headcount to four FTEs, cut operating costs materially, and ended the year with US$1.1M cash and no debt, positioning itself for a focused US-only model. Management is pursuing strategic initiatives including potential capital raises, partnerships, and M&A to accelerate recovery from the higher-margin Hydralyte PLUS product base. Key points: Successful structural reset to focused US-only operating model following divestiture of non-US assets, with deliberate channel refinement and SKU rationalization improving margin quality; Significant cost restructuring reduced headcount to four FTEs (further reduced to two post-year end in February 2026) with outsourced finance and marketing support, materially lowering ongoing monthly cost base; Strong balance sheet position with US$1.1M cash, no debt, and simplified capital structure providing improved financial flexibility for future growth initiatives
Recent Announcements
Notice of initial substantial holder
Longhorn Capital Pty Ltd became a substantial holder of The Hydration Pharmaceuticals Company Limited on 25/05/2026, acquiring 33,492,749 FPO shares representing 7.77% voting power for consideration of $107,476.19.
Ceasing to be a substantial holder
Regal Partners Funds Management Pty Ltd and its ceased to be a substantial holder.
Appendix 4E and Annual Report
The Hydration Pharmaceuticals Company Limited (ASX: HPC) reported a significant operational restructuring in FY2025, with revenue declining 22.9% to US$2.47M and a net loss of US$2.86M (versus prior-year profit of US$2.67M), following the divestiture of non-US assets and deliberate SKU rationalization prioritizing margin quality over growth. The company reduced headcount to four FTEs, cut operating costs materially, and ended the year with US$1.1M cash and no debt, positioning itself for a focused US-only model. Management is pursuing strategic initiatives including potential capital raises, partnerships, and M&A to accelerate recovery from the higher-margin Hydralyte PLUS product base. Key points: Successful structural reset to focused US-only operating model following divestiture of non-US assets, with deliberate channel refinement and SKU rationalization improving margin quality; Significant cost restructuring reduced headcount to four FTEs (further reduced to two post-year end in February 2026) with outsourced finance and marketing support, materially lowering ongoing monthly cost base; Strong balance sheet position with US$1.1M cash, no debt, and simplified capital structure providing improved financial flexibility for future growth initiatives
Get real-time alerts for HPC
Receive AI-powered earnings summaries and instant notifications when The Hydration Pharmaceuticals Company Limited releases results.
Register Free